Looking beyond current advances in personalized or stratified cancer therapy, I think that early intervention – before the disease becomes advanced – will be the future…
In Conversation
Singapore is often the first market for [Pfizer's] product launches in Emerging Asia, new regulatory strategies to optimize launch timelines, and digital innovations. We act as…
Healthcare is a key area within our plan moving forward, and this comes as no surprise considering that four percent of the Singaporean economy already comes…
Value-Based healthcare in this part of the world will be implemented in different ways. It will come less through contracts, but more through pricing regulations
We need doctors, nurses and other healthcare providers to be willing to go the extra mile to monitor patients outside of hospital settings
The importance and urgency of developing a vaccine during the COVID-19 pandemic is obvious
Our plan is ambitious and optimistic; we put our faith in the country and will continue to do so.
Regulators are in a difficult position and still coming to understand how to define these new technologies. Greater alignment with the US does seem to be…
[Vision 2030] is compelling because it is leading the transformation from an oil-based economy to a knowledge-based economy. In doing so, the country put its healthcare…
Turkey has a unique value proposition, bringing European perfection at an affordable cost, and Novartis has made investments to make the country a quality export launchpad
Unlike some other countries, where quality data is locked in specific hospitals, we have excellent data across the country and a central personal register, which is…
The days of picking low hanging fruit are over; the only strategies that will be rewarded are those based on deep and long-term investment in local…
